Sampaio Rita C, Tanus-Santos Jose E, Melo Silvia E S F C, Hyslop Stephen, Franchini Kleber G, Luca Iara M, Moreno Heitor
Department of Pharmacology, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil 14049-900.
Chest. 2002 Oct;122(4):1412-20. doi: 10.1378/chest.122.4.1412.
We compared the myocardial lesions caused by the long-term inhibition of nitric oxide (NO) biosynthesis with those associated with renovascular hypertension (two-kidney, one-clip model [2K-1C]) and superimposed streptozotocin-induced diabetes mellitus (DM).
Prospective trial.
University laboratory.
Male Wistar rats were classified into the following groups: (1) a control group; (2) the L-NAME group (treatment with the NO synthase inhibitor N(omega)-nitro-L-arginine methyl ester [L-NAME], 75 micro mol per rat per day, orally); (3) the 2K-1C group (renovascular hypertension); (4) the DM group (treatment with streptozotocin, 60 mg/kg via intraperitoneal route); and (5) the 2K-1C plus DM group (renovascular hypertension and streptozotocin-induced DM). Arterial BP was measured by a tail-cuff method for 3 weeks, after which histologic and stereological analysis of the heart was done and cardiac NO synthase type 3 (NOS3) levels were assessed by Western blotting. The circulating levels of nitrates/nitrites and thromboxane B(2) (TXB(2), the stable metabolite of thromboxane A(2)) were also measured.
In DM and 2K-1C rats, the myocardial lesions consisted mainly of recent myocardial infarcts, which were more severe in the 2K-1C plus DM group. In L-NAME-treated rats, multiple foci of reparative fibrosis and fresh myocardial necrosis resembled the severe lesions found in the 2K-1C plus DM group. Although NOS3 protein expression increased (19 to 44%; p < 0.05) in all treated groups, serum nitrate/nitrite levels decreased only in the L-NAME group and the 2K-1C plus DM group. These two groups also showed a more pronounced increase in TXB(2) concentrations.
These results indicate that the association of hypertension and DM mimics the alterations induced by L-NAME in rats, which suggests a role for NO in the pathophysiology of hypertensive-diabetic cardiomyopathy.
我们比较了长期抑制一氧化氮(NO)生物合成所导致的心肌损伤与肾血管性高血压(两肾一夹模型[2K-1C])以及叠加链脲佐菌素诱导的糖尿病(DM)相关的心肌损伤。
前瞻性试验。
大学实验室。
雄性Wistar大鼠被分为以下几组:(1)对照组;(2)L-NAME组(用NO合酶抑制剂N(ω)-硝基-L-精氨酸甲酯[L-NAME]治疗,每只大鼠每天口服75微摩尔);(3)2K-1C组(肾血管性高血压);(4)DM组(用链脲佐菌素治疗,腹腔注射60毫克/千克);(5)2K-1C加DM组(肾血管性高血压和链脲佐菌素诱导的DM)。用尾套法测量动脉血压3周,之后对心脏进行组织学和体视学分析,并通过蛋白质印迹法评估心脏3型NO合酶(NOS3)水平。还测量了循环中硝酸盐/亚硝酸盐和血栓素B2(TXB2,血栓素A2的稳定代谢产物)的水平。
在DM和2K-1C大鼠中,心肌损伤主要由近期心肌梗死组成,在2K-1C加DM组中更严重。在L-NAME治疗的大鼠中,修复性纤维化和新鲜心肌坏死的多个病灶类似于2K-1C加DM组中发现的严重损伤。尽管所有治疗组中NOS3蛋白表达均增加(19%至44%;p<0.05),但血清硝酸盐/亚硝酸盐水平仅在L-NAME组和2K-1C加DM组中降低。这两组的TXB2浓度也有更明显的升高。
这些结果表明,高血压和DM的联合作用模拟了L-NAME在大鼠中诱导的改变,这表明NO在高血压糖尿病性心肌病的病理生理学中起作用。